The weight-loss peptide landscape has been transformed in less than a decade. What began with the approval of semaglutide (Ozempic/Wegovy) as a GLP-1 receptor agonist has rapidly evolved through the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound) and now to retatrutide — a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. For researchers attempting to understand the comparative evidence base, the distinctions matter significantly.
This article presents a side-by-side comparison of all three compounds based exclusively on published clinical trial data and peer-reviewed pharmacological research.
Mechanism of Action: How They Differ
Understanding these three compounds begins with their receptor targets — the incretin hormone receptors that govern appetite, insulin secretion, and energy balance.
| Compound | GLP-1R | GIPR | Glucagon R | Administration |
|---|---|---|---|---|
| Semaglutide | Agonist | — | — | Weekly SQ or oral |
| Tirzepatide | Agonist | Agonist | — | Weekly SQ |
| Retatrutide | Agonist | Agonist | Agonist | Weekly SQ |
The addition of glucagon receptor agonism in retatrutide is the critical differentiator. GLP-1 and GIP agonism suppress appetite and enhance insulin secretion — but glucagon receptor activation directly increases energy expenditure through thermogenesis and hepatic fat oxidation. This creates a third mechanism for weight loss that neither semaglutide nor tirzepatide can access.
Preclinical and clinical researchers have invested decades into understanding incretin hormone biology — the foundation of this entire peptide class.
Efficacy: What the Clinical Trials Show
Weight loss outcomes across these three compounds have been studied in randomized, placebo-controlled trials. The following data represents peak published results at each compound's highest studied dose.
| Compound | Max Dose | Trial Duration | Mean Weight Loss | % Achieving >20% loss |
|---|---|---|---|---|
| Semaglutide 2.4 mg | 2.4 mg/week | 68 weeks (STEP 1) | ~14.9% | ~32% |
| Tirzepatide 15 mg | 15 mg/week | 72 weeks (SURMOUNT-1) | ~20.9% | ~57% |
| Retatrutide 12 mg | 12 mg/week | 48 weeks (Phase 2) | ~24.2% | >60% (est.) |
The 24.2% mean weight loss seen in retatrutide's Phase 2 trial at 48 weeks — still increasing at the last measured timepoint — represents the highest weight reduction ever reported for any pharmacological agent in a randomized clinical trial. For context, bariatric surgery typically achieves 25–30% total body weight loss; retatrutide's trajectory suggests it may approach surgical outcomes in some patients.
Side Effect Profiles
All three compounds share a class-related GI side effect profile, primarily driven by GLP-1 receptor agonism slowing gastric emptying. The intensity and management strategy is broadly similar across all three.
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | ~44% | ~31% | ~45–55% |
| Vomiting | ~24% | ~16% | ~20% |
| Diarrhea | ~30% | ~23% | ~20% |
| Constipation | ~24% | ~17% | ~15% |
| Heart rate increase | Mild (+2–3 bpm) | Mild (+2–3 bpm) | Moderate (+5–10 bpm) |
| Injection site reaction | Common, mild | Common, mild | Common, mild |
Retatrutide's glucagon receptor component introduces one notable difference: a more pronounced increase in resting heart rate compared to semaglutide and tirzepatide. This appears to be a direct pharmacological effect of glucagon agonism and warrants monitoring in individuals with pre-existing cardiovascular conditions.
Muscle Mass Preservation
One underappreciated concern with all effective weight-loss agents is the proportion of lean mass lost alongside fat. In the SURMOUNT-1 trial, tirzepatide participants lost approximately 33% of their weight as lean mass — broadly consistent with what is seen with semaglutide. Retatrutide's Phase 2 trial did not publish granular body composition data, and Phase 3 results are awaited.
For all three compounds, resistance training and adequate protein intake (1.6–2.2 g/kg bodyweight) are strongly recommended to mitigate lean mass loss during the weight reduction phase.
Research Summary
The progression from semaglutide to tirzepatide to retatrutide represents a meaningful stepwise improvement in weight loss efficacy at each generation. The addition of glucagon receptor agonism in retatrutide introduces a novel energy expenditure mechanism that appears to drive superior outcomes. However, the clinical evidence base for retatrutide remains in Phase 3, and definitive long-term safety and efficacy data is not yet available. Semaglutide and tirzepatide, by contrast, have extensive Phase 3 and real-world data supporting their profiles.